Clinicopathological characteristics of kidney injury in non-small cell lung cancer patients under combination therapy including pembrolizumab

Published: Aug 18, 2021
Abstract
Combination therapy, consisting of immune checkpoint inhibitors and traditional chemotherapeutic agents, has significantly improved the clinical outcomes of non-small cell lung cancer. Therefore, it will be a promising first-line therapy, whereas, there is a prospect that associated kidney injury may increase during treatment. We presented four patients, diagnosed with advanced non-small cell lung cancer, who received combination therapy,...
Paper Details
Title
Clinicopathological characteristics of kidney injury in non-small cell lung cancer patients under combination therapy including pembrolizumab
Published Date
Aug 18, 2021
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.